Abstract 2163
Background
Germ cell tumor patients with intermediate prognosis (IPGCT) according to the IGCCCG classification represent a heterogeneous group exhibiting a variety of clinical features. We established a registry to identify prognostic markers to further characterize IPGCT.
Methods
A retrospective observational study was performed. Eligibility criteria were intermediate prognosis according to IGCCCG criteria, male sex, age ≥16 years. Patients were diagnosed from 1979 to 2014. Clinical characteristics were evaluated with uni- and multivariate analyses to detect new prognosticators. AFP and HCG were available in 85% and LDH levels in 72% of the cases, respectively. Overall survival (OS) was the primary endpoint.
Results
The database included n = 707 IPGCT with a median follow-up of 8.6 years (IQR: 14.4). First line cisplatin-based chemotherapy was administered to 701 patients (99%) and the 5-year OS rate was 87%. First diagnosis in the 1980s (n = 115), the 1990s (n = 158), and after 2000 (n = 434) were associated with 5-year OS rates of 81%, 85%, and 89%, respectively. Statistical analyses revealed AFP and LDH, but not HCG levels prior chemotherapy as prognosticators. A patient stratification according to AFP levels <1000 IU/ml (n = 360), 1000 to 2000 IU/ml (n = 77), >2000 to 5000 IU/ml (n = 93) and >5000 (n = 74) IU/ml prior first course of chemotherapy, revealed a significant correlation between AFP levels and OS, associated with 5-year OS rates of 89%, 87%, 86% and 82%, respectively (p = 0.037). LDH levels prior chemotherapy also correlated with outcome, associated with five-year OS rates of 92% for <2 ULN (n = 289), 88% for ≥2 to 3 ULN (n = 91), 80% for >3 to 4 ULN (n = 37), and 78% for >4 ULN (n = 89), respectively (p = 0.011). In multivariate analysis cut-off values of AFP levels >6000 IU/ml (p = 0.036; HR 2.096) and LHD levels >2 ULN (p = 0.02; HR 2.121) or > 3 ULN (p = <0.001; HR 2.305) were independent prognosticators for OS.
Conclusions
Prognostication according to LDH and AFP levels prior chemotherapy could offer a new approach to stratify IPGCT. The largest fraction of patients had AFP levels <2000 IU/ml and LDH <2 ULN associated with an outcome similar to the good prognosis category. These results need to be confirmed in the upcoming IGCCCG reclassification.
Clinical trial identification
Legal entity responsible for the study
Christoph Seidel.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract